Results 151 to 160 of about 4,310 (188)
Potential role of the comprehensive tooth extraction procedure in preventing medication related osteonecrosis of the jaw (MRONJ): a prospective cohort study. [PDF]
Orphanet J Rare DisWang Y +11 more
europepmc +1 more source
Fibula flap versus soft tissue flap with reconstruction plate for mandibular stage 3 medication-related osteonecrosis of the jaw: a retrospective cohort study. [PDF]
BMC Oral HealthLin Y +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Infection and Medication-related Osteonecrosis of the Jaw
Journal of Dental Research, 2015Medication-related osteonecrosis of the jaw (MRONJ), although initially believed to be exclusively associated with bisphosphonates, has been implicated in recent reports with additional drugs, especially the bone antiresorptive denosumab. The pathophysiology has not been fully elucidated, and no causal association between bone antiresorptive regimens ...
Michael Pazianas, D K Dhariwal
exaly +3 more sources
Medication-related osteonecrosis of the jaw
InnovAiT: Education and inspiration for general practice, 2020Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but well-documented, complication following the administration of anti-resorptive and anti-angiogenic drugs. MRONJ has a negative effect on quality of life, and can result in reduced social contact, pain and masticatory difficulties. Prescription of implicated medication is within the remit
Kishan Patel +2 more
openaire +2 more sources
Management of Medication-Related Osteonecrosis of the Jaw
Oral and Maxillofacial Surgery Clinics of North America, 2015Medication-related osteonecrosis of the jaw (MRONJ) primarily involves patients receiving intravenous bisphosphonates for treatment of skeletal-related malignancies, oral bisphosphonates, and denosumab. There is no consensus regarding the clinical management of MRONJ.
William Bradford, Williams +1 more
openaire +2 more sources
Preventing medication-related osteonecrosis of the jaw
BMJ, 2019### What you need to know Osteonecrosis of the jaw is a severe adverse effect reported with certain drugs commonly used in the treatment of cancers and osteoporosis. Although rare, it can severely impair quality of life.1 The number and type of drugs associated with osteonecrosis of the jaw continue to increase, as do their indications.
Lara, Zebic, Vinod, Patel
openaire +2 more sources
Interventions for managing medication-related osteonecrosis of the jaw
Cochrane Database of Systematic Reviews, 2022Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab, and antiangiogenic agents), and involves the progressive destruction of bone in the mandible or maxilla.
Natalie H, Beth-Tasdogan +4 more
openaire +2 more sources
Medication-Related Osteonecrosis of the Jaws
2021Medication-related osteonecrosis of the jaw is an area of exposed bone in the maxilla or mandible that does not heal over a period of 6–8 weeks. It is a well-known side effect of bisphosphonate therapy, first described by Marx in 2003. More recently, other drugs have been incriminated: monoclonal antibodies inhibiting osteoclastic activity, such as ...
Leonor Costa Mendes, Bruno Courtois
openaire +1 more source
Medication-Related Osteonecrosis of the Jaw
New England Journal of Medicine, 2023Yu-Feng Chen, Hong-Po Chang
+5 more sources
Pain characteristics in medication-related osteonecrosis of the jaws
Supportive Care in Cancer, 2020To characterise pain from medication-related osteonecrosis of the jaws (MRONJ) and the effects of antimicrobial treatment on it.Data from files of patients diagnosed with MRONJ according to the position paper of the American Association of Oral and Maxillofacial Surgeons (2014) and Multinational Association of Supportive Care in Cancer and American ...
Yaron, Haviv +5 more
openaire +2 more sources